FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE REV. 12-2004) TRANSMITTAL LETTER TO THE UNITED STATES PP023362.0003 U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/US2004/031617 23 September 2004 23 September 2003 TITLE OF INVENTION NOVEL THERAPEUTIC TARGETS IN CANCER APPLICANT(S) FOR DO/EO/US Daveid W. MORRIS and Marc S. MALANDRO Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. \boxtimes This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. П 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), 3. (9) and (24) indicated below. The US has been elected (Article 31). 4. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). b. 🗆 has been communicated by the International Bureau. c. 🔯 is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🗆 is attached hereto. b. 🗆 has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) a. 🗆 are attached hereto (required only if not communicated by the International Bureau). b. 🗆 have been communicated by the International Bureau. c. 🗆 have not been made; however, the time limit for making such amendments has NOT expired. d. 🗆 have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 8. 9. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. A FIRST preliminary amendment.

- 16. A SECOND or SUBSEQUENT preliminary amendment.
- 17. A substitute specification.
- 18.

 A power of attorney and/or change of address letter.
- 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 1.825.
- 20. A second copy of the published International Application under 35 U.S.C. 154(d)(4).
- 21. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).
- 22. Express Mail Label No. EV525243903US
- 23. Other items or information:

copy of International Search Report including Wwirtten Opinion of teh International Searching Authority Postcard and cheque

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1	U.S. APPLICATION NO (if known; see 37 CFR 1.5)			INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER				
	Unassigned 956			PCT/US20	PCT/US2004/031617				PP023362.0003		
	24. The following							Арр	licant use	Office use	
	🛭 a) Basic natio	a) Basic national fee\$300.00							\$300.00		
	⊠ b) Examination fee							\$	\$200.00		
⊠ c) Search fee								\$	\$500.00		
TOTAL OF ABOVE CALCULATIONS = \$1000.00								\$	\$1,000.00		
	Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							.	\$1,000.00		
	Total Sheets	Extra Sheets	Number o	Number of each additional 50 or refraction thereof (round up to a whole							
	197 - 100 =	97 /50 =		2		x	\$250.00	\$	\$500.00		
	Surcharge of \$130 earliest claimed pr	Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).						\$	\$130.00		
	CLAIMS			NUMBER EXTRA		RATE					
	Total claims	55	- 20 =	35	х		\$50.00	\$	\$1,750.00		
1	Independent claim	s 10	- 3=	7	х		\$200.00	\$	\$1,400.00		
	MULTIPLE DEPE	NDENT CLAIMS	(if applicable)	×	+		\$360.00	\$	\$360.00		
		TOTAL OF ABOVE CALCULATIONS =						\$	\$5,140.00		
		Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.						\$	\$0.00		
-		SUBTOTAL =						\$	\$5,140.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).								\$	\$0.00	-···	
	TOTAL NATIONAL FEE							\$	\$5,140.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +								\$	\$0.00		
TOTAL FEES ENCLOSED =								\$	\$5,140.00		
Amount to be refunded:									· · · · · · · · · · · · · · · · · · ·	\$	
Amount to be charged:										\$	
	a. A check in the amount of \$ \$5,140.00 to cover the above fees is enclosed.										
	b. Please charge my Deposit Account No. in the amount of to cover the above fees. A duplicate copy of this sheet is										
	c. 🔼 The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment										
		to Deposit Account No03-1664 A duplicate copy of this sheet is enclosed.									
	d. Fees are informati	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.											
	SEND ALL CORR	ESPONDENCE T	⁻O:		abe A				lex ander		
	Chiron Corporation SIGNATURE										
	Intellectual Property R-338 P.O. Box 8097 Lisa E. A								lexander		
		Emeryville, California 94662-8097 NAME									
	US										
	Customer No. 27	Tustomer No. 27476							TION NUMBER		

PATENT PP023362.0003 3000005556

APRINCECTULINE 2006

PATENT COOPERATION TREATY IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

International Application No. PCT/US2004/031617

International Filing Date 23 September 2004

Priority Date Claimed 23 September 2003

Title of Invention

NOVEL TEHRAPEUTIC TARGETS IN CANCER

Applicants for DO/EO/US:

David W. MORRIS and Marc S. MALANDRO

CERTIFICATE OF MAILING BY EXPRESS MAIL

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Express Mail Mailing Label No.: EV525243903US

Date of Deposit: 23 March 2006

I hereby certify that the attached Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 U.S.C.371, copy of unsigned Declaration for Patent Application, copy of Published Specification, copy of International Search Report, Check No. 9047 in the amount \$5140.00 and Postal Receipt Card are being deposited with the United Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R.1.10 on the date indicated above and addressed to the Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 23 March 2006

Melodi K Dice

CHIRON CORPORATION 4560 Horton Street Emeryville, California 94608 United States of America